[go: up one dir, main page]

PE20000986A1 - Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos - Google Patents

Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos

Info

Publication number
PE20000986A1
PE20000986A1 PE1999000862A PE00086299A PE20000986A1 PE 20000986 A1 PE20000986 A1 PE 20000986A1 PE 1999000862 A PE1999000862 A PE 1999000862A PE 00086299 A PE00086299 A PE 00086299A PE 20000986 A1 PE20000986 A1 PE 20000986A1
Authority
PE
Peru
Prior art keywords
cr13r14
alkyl
ona
quinolin
cyane
Prior art date
Application number
PE1999000862A
Other languages
English (en)
Inventor
Joseph Peter Lyssikatos
Greca Susan Deborah La
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20000986A1 publication Critical patent/PE20000986A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A DERIVADOS DE QUINOLIN-2-ONA ALQUINIL SUSTITUIDOS DE FORMULA I, DONDE R1 ES H, ALQUILO C1-C10, (CR13R14)qCOR12, (CR13R14)qCOOR15, (CR13R14)qOR12, ENTRE OTROS; q ES 1-5; R2 ES HALO, CIANO, COOR15; R3, R4, R5, R6 Y R7 SON H, ALQUILO C1-C10, ALQUENILO C2-C10, HALO, CIANO, NITRO, ENTRE OTROS; R8 ES H, OR12, NR12R13, NR12COR13, CIANO, COOR13, SR12, (CR13R14)t(HETEROCICLO DE 4-10 MIEMBROS), R9 ES (CR13R14)t(IMIDAZOLILO); t ES 0-5; R12 ES H, ALQUILO C1-C10, (CR13R14)t(CICLOALQUILO C3-C10), (CR13R14)t(ARILO C6-C10), ENTRE OTROS; R13 Y R14 SON H, ALQUILO C1-C6; R15 ES R12 Y NO ES H; R16 ES R12 Y SiR17R18R19; R17, R18, R19 NO SON H; UNO DE R3, R4 Y R5 ES (CR13R14)tC­CR16. SON COMPUESTOS PREFERIDOS 6-[(4-CLOROFENIL)HIDROXI-(3-METIL-3H-IMIDAZOL-4-IL)METIL]-4-(3-ETINILFENIL)-1-METIL-1H-QUINOLIN-2-ONA (ENANTIOMERO A o B), ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS UN AGENTE ANTITUMORAL COMO INHIBIDORES DE MITOSIS, AGENTES ALQUILANTES, ANTIMETABOLITOS, ANTIBIOTICOS INTERCALANTES, INHIBIDORES DEL FACTOR DE CRECIMIENTO, ENTRE OTROS. EL COMPUESTO I INHIBE A LA FARNESIL TRANSFERASA Y PUEDE SER UTIL PARA EL TRATAMIENTO DEL DESARROLLO ANORMAL DE CELULAS, CANCER, DE PULMON, HUESOS, PANCREAS, PIEL, CABEZA, GARGANTA, MELANOMA CUTANEO; ENFERMEDAD PROLIFERATIVA BENIGNA COMO PSORIASIS
PE1999000862A 1998-08-27 1999-08-26 Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos PE20000986A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9814598P 1998-08-27 1998-08-27

Publications (1)

Publication Number Publication Date
PE20000986A1 true PE20000986A1 (es) 2000-09-30

Family

ID=22267481

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000862A PE20000986A1 (es) 1998-08-27 1999-08-26 Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos

Country Status (40)

Country Link
US (3) US6150377A (es)
EP (1) EP1107963B1 (es)
JP (1) JP3495706B2 (es)
KR (1) KR20010072991A (es)
CN (1) CN1314904A (es)
AP (1) AP2001002079A0 (es)
AT (1) ATE321037T1 (es)
AU (1) AU4925499A (es)
BG (1) BG105365A (es)
BR (1) BRPI9913138B8 (es)
CA (2) CA2341690C (es)
CO (1) CO5130017A1 (es)
CZ (1) CZ2001660A3 (es)
DE (1) DE69930518T2 (es)
DZ (1) DZ2880A1 (es)
EA (1) EA200100135A1 (es)
EE (1) EE200100118A (es)
ES (1) ES2259237T3 (es)
GE (1) GEP20033001B (es)
GT (1) GT199900140A (es)
HK (1) HK1039123A1 (es)
HR (1) HRP20010142A2 (es)
HU (1) HUP0103228A3 (es)
ID (1) ID27562A (es)
IL (1) IL141239A0 (es)
IS (1) IS5818A (es)
MA (1) MA26680A1 (es)
NO (1) NO20010964L (es)
NZ (1) NZ509372A (es)
OA (1) OA11645A (es)
PA (1) PA8480101A1 (es)
PE (1) PE20000986A1 (es)
PL (1) PL346426A1 (es)
SK (1) SK2442001A3 (es)
SV (1) SV1999000141A (es)
TN (1) TNSN99162A1 (es)
TR (1) TR200101343T2 (es)
UY (1) UY25682A1 (es)
WO (1) WO2000012499A1 (es)
ZA (1) ZA200101173B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114503A1 (en) * 1997-06-16 2003-06-19 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
HRP20000904A2 (en) * 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
ES2237125T3 (es) * 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
ATE321037T1 (de) * 1998-08-27 2006-04-15 Pfizer Prod Inc Als antikrebsmittel verwendbare alkinyl- substituierte chinolin-2-on-derivate
ES2243228T3 (es) 1999-02-11 2005-12-01 Pfizer Products Inc. Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
DE60130976T2 (de) 2000-02-24 2008-07-17 Janssen Pharmaceutica N.V. Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
WO2002024682A1 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
AU2001293835A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
ES2313991T3 (es) * 2000-09-25 2009-03-16 Janssen Pharmaceutica Nv Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
JP4974437B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−［（置換フェニル）メチル］−キノリンおよびキナゾリン誘導体
US7153958B2 (en) 2000-11-21 2006-12-26 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
EP1395577A1 (en) * 2000-12-19 2004-03-10 Pfizer Products Inc. Crystal forms of 6- (4-chloro-phenyl)-hydroxy-(-3-methyl-3h-imidaol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
WO2002051835A1 (en) * 2000-12-27 2002-07-04 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
WO2002056884A2 (en) * 2001-01-22 2002-07-25 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
AU2002253101B2 (en) * 2001-03-12 2007-08-09 Janssen Pharmaceutica N.V. Process for the preparation of imidazole compounds
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
US20050165053A1 (en) * 2001-06-04 2005-07-28 Cytovia, Inc. Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6713462B2 (en) 2001-06-21 2004-03-30 Ariad Pharmaceuticals, Inc. Quinolinones and uses thereof
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
DE60231646D1 (de) 2001-12-19 2009-04-30 Janssen Pharmaceutica Nv Durch c-verbundene imidazole substituierte 1,8-annellierten chinolon-derivate als farnesyl transferase inhibitoren
WO2003080058A1 (en) 2002-03-22 2003-10-02 Janssen Pharmaceutica. N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
ES2271574T3 (es) 2002-04-15 2007-04-16 Janssen Pharmaceutica N.V. Derivados triciclicos de quinazolina inhibidores de la farnesiltransferasa, sustituidos con imidazoles o triazoles enlazados al carbono.
DK1585743T3 (da) * 2002-12-19 2007-09-17 Pfizer 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme
WO2005051392A1 (en) 2003-11-20 2005-06-09 Children's Hospital Medical Center Gtpase inhibitors and methods of use
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2561516A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
MX2007002312A (es) 2004-08-26 2007-04-16 Pfizer Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa.
BRPI0514687A (pt) * 2004-08-26 2008-06-17 Pfizer compostos amino heteroarila como inibidores de proteìna tirosina cinase
SI1784396T1 (sl) * 2004-08-26 2011-03-31 Pfizer S pirazolom substituirane aminoheteroarilne spojine kot zaviralci protein-kinaze
SI2362218T1 (sl) 2004-11-05 2014-12-31 Janssen Pharmaceutica N.V. Postopki za spremljanje učinkovitosti inhibitorjev farneziltransferaze
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
CA2617056A1 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
GEP20125398B (en) * 2005-09-07 2012-02-27 Amjen Freemont Ink Human monoclonal antibodies to activin receptor-like kinase-1
CA2623125A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2009521470A (ja) 2005-12-23 2009-06-04 リンク メディシン コーポレイション シヌクレイン障害の治療
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EP2021335B1 (en) 2006-04-20 2011-05-25 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
ES2565238T3 (es) 2006-04-20 2016-04-01 Janssen Pharmaceutica N.V. Inhibidores de la c-fms quinasa
CN101490046A (zh) 2006-05-09 2009-07-22 辉瑞产品公司 环烷基氨基酸衍生物及其药物组合物
ES2546066T3 (es) 2006-08-21 2015-09-18 F. Hoffmann-La Roche Ag Terapia tumoral con un anticuerpo anti-VEGF
WO2008112525A2 (en) * 2007-03-09 2008-09-18 Link Medicine Corporation Treatment of lysosomal storage diseases
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
BRPI0920927A2 (pt) 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
EP2401613A2 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2013527748A (ja) 2010-03-03 2013-07-04 オーエスアイ・ファーマシューティカルズ，エルエルシー インスリン様増殖因子１受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー
EP2542893A2 (en) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
US9303046B2 (en) 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
TWI710642B (zh) 2015-08-17 2020-11-21 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶（farnesyltransferase）抑制劑治療癌症病患之方法
KR20180100125A (ko) 2015-12-03 2018-09-07 아지오스 파마슈티컬스 아이엔씨. Mtap 널 암을 치료하기 위한 mat2a 억제제
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
KR20190082247A (ko) 2016-11-03 2019-07-09 쿠라 온콜로지, 인크. 파르네실전달효소 억제제를 이용하여 암 환자를 치료하는 방법
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
KR20200090982A (ko) 2017-02-21 2020-07-29 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
JP7325400B2 (ja) 2017-08-07 2023-08-14 クラ オンコロジー， インコーポレイテッド ファルネシルトランスフェラーゼ阻害剤を用いてがんを治療する方法
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
CA3117968A1 (en) 2018-11-01 2020-05-07 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
JP2022514654A (ja) 2018-12-21 2022-02-14 クラ オンコロジー， インコーポレイテッド 扁平上皮癌のための治療法
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
SG11202110472WA (en) 2019-03-29 2021-10-28 Kura Oncology Inc Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
TW202102218A (zh) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
JP7718659B2 (ja) 2019-08-16 2025-08-05 チルドレンズ ホスピタル メディカル センター Ｃｄｃ４２特異的阻害剤で対象を治療する方法
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
WO1997021701A1 (en) * 1995-12-08 1997-06-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
ATE321037T1 (de) * 1998-08-27 2006-04-15 Pfizer Prod Inc Als antikrebsmittel verwendbare alkinyl- substituierte chinolin-2-on-derivate

Also Published As

Publication number Publication date
ES2259237T3 (es) 2006-09-16
NZ509372A (en) 2003-08-29
TNSN99162A1 (fr) 2005-11-10
CZ2001660A3 (cs) 2002-05-15
EE200100118A (et) 2002-06-17
US6579887B2 (en) 2003-06-17
AU4925499A (en) 2000-03-21
CN1314904A (zh) 2001-09-26
CA2341690C (en) 2007-04-17
US6294552B1 (en) 2001-09-25
EP1107963B1 (en) 2006-03-22
ATE321037T1 (de) 2006-04-15
NO20010964L (no) 2001-04-26
DZ2880A1 (fr) 2003-12-15
NO20010964D0 (no) 2001-02-26
HK1039123A1 (zh) 2002-04-12
GT199900140A (es) 2001-02-14
JP2002523504A (ja) 2002-07-30
CA2578326C (en) 2009-11-24
ID27562A (id) 2001-04-12
BR9913138B1 (pt) 2013-11-05
HUP0103228A3 (en) 2003-01-28
JP3495706B2 (ja) 2004-02-09
BG105365A (en) 2001-11-30
TR200101343T2 (tr) 2001-09-21
WO2000012499A1 (en) 2000-03-09
EP1107963A1 (en) 2001-06-20
US6150377A (en) 2000-11-21
OA11645A (en) 2004-11-16
IS5818A (is) 2001-01-19
PL346426A1 (en) 2002-02-11
HUP0103228A2 (hu) 2002-02-28
DE69930518T2 (de) 2006-09-21
BRPI9913138B8 (pt) 2016-05-17
HRP20010142A2 (en) 2002-02-28
BR9913138A (pt) 2001-05-08
CA2578326A1 (en) 2000-03-09
MA26680A1 (fr) 2004-12-20
DE69930518D1 (de) 2006-05-11
CA2341690A1 (en) 2000-03-09
ZA200101173B (en) 2002-04-12
CO5130017A1 (es) 2002-02-27
EA200100135A1 (ru) 2001-08-27
SV1999000141A (es) 2000-07-06
KR20010072991A (ko) 2001-07-31
PA8480101A1 (es) 2003-06-30
GEP20033001B (en) 2003-06-25
US20020128287A1 (en) 2002-09-12
AP2001002079A0 (en) 2001-03-31
IL141239A0 (en) 2002-03-10
UY25682A1 (es) 2000-03-31
SK2442001A3 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
PE20000986A1 (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos
PE20000334A1 (es) Compuestos para el tratamiento de la isquemia
PE20001093A1 (es) 3-amino-4-aril-maleimidas como inhibidores de gsk-3
PE20011334A1 (es) Compuestos y composiciones de indazol de formula (i)
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
AR018330A1 (es) Composiciones farmaceuticas que comprenden macrolidos como agentes activos para la terapia y profilaxis de las enfermedades de la piel
PE20010126A1 (es) Pirrolotriazinas como inhibidores de cinasas
AR028815A1 (es) Epotilonas c-21 modificadas
PE20001464A1 (es) Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos
PE20030200A1 (es) Bencimidazol como inhibidores de las map quinasas
PE20021006A1 (es) Derivados de 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la proteinquinasa
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
AR006867A1 (es) Composición topica para la piel que comprende un compuesto oxa-diácido, su uso para preparar un medicamento para tratar condiciones de la piel y métodos cosméticos no terapéuticos para el pulido de la piel y para suavizar el cabello que aplican dicho compuesto.
NZ505968A (en) Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases
PE20030226A1 (es) Compuestos arilicos sustituidos con quinuclidinas para el tratamiento de enfermedades
HRP20031098B1 (en) Beta-amino tetrahydroimidazo (1,2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
PE20020338A1 (es) DERIVADOS DEL 3-INDOLIL-4-FENIL-1H-PIRROL-2,5-DIONA QUE INHIBEN LA GLUCOGENO SINTASA QUINASA-3ß (GSK-3ß)
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
PE20121010A1 (es) Derivados de bencimidazol
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
PE20050730A1 (es) Derivados de 2,5-dihidropirrol 2,2-disustituidos como inhibidores de quinesinas mitoticas
PE20011118A1 (es) (+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3h-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1h-quinolein-2-ona como compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
PE20070832A1 (es) Derivados de piridazinona como inhibidores de la tirosina quinasa
ES2073246T3 (es) Derivados de pirazina.

Legal Events

Date Code Title Description
FC Refusal